Related Experiment Video
Updated: May 28, 2026
08:08
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
The SLC25A45-TML Axis as a Biological Foundation for a Multivariable Plasma Metabolite Signature for High-Precision
Liang Zhao1, Raghothama Chaerkady1, Naseruddin Höti1
1Complete Omics Inc., Baltimore, MD 21227, USA.
Cancers
|May 27, 2026
Summary
This study identifies key metabolic shifts in prostate cancer (PCa) patients, revealing a novel diagnostic signature for improved detection. The findings highlight the SLC25A45-TML axis as a potential non-invasive biomarker for PCa.
Area of Science:
- Metabolomics
- Biochemistry
- Oncology
Background:
- Prostate cancer (PCa) poses a significant health challenge.
- Current PSA screening lacks specificity, leading to overdiagnosis.
Purpose of the Study:
- To identify novel biomarkers for improved PCa detection.
- To investigate metabolic reprogramming in PCa.
Main Methods:
- Targeted metabolomics profiling of 43 metabolites in plasma using the Complete360®-MyMeta platform.
- Analysis of carnitine, polyamine, and methylation networks in PCa patients and controls.
Main Results:
- Identified 28 significantly altered metabolites, including depleted TML and putrescine, and elevated L-acetylcarnitine and sarcosine.
- Developed a multivariable diagnostic signature with an AUC of 0.99 using metabolic ratios.
- Linked metabolic shifts to tumoral "metabolic sink" and SLC25A45 transporter activity.
Conclusions:
- The SLC25A45-TML axis offers a mechanistically grounded, stage-independent liquid biopsy.
- This study provides a proof-of-concept for a non-invasive framework to enhance PCa detection.
